Form 4: Achieve Life Sciences CEO John Bencich Acquires 10,000 Shares in Registered Direct Offering

Achieve Life Sciences CEO John Bencich purchased 10,000 shares of common stock and warrants in a registered direct offering.

Summary

• On March 4, 2024, John Bencich, CEO of Achieve Life Sciences, acquired 10,000 shares of common stock at $4.585 per share, totaling $45,850.
• The purchase was part of a registered direct offering (RDO) under a Securities Purchase Agreement (SPA) dated February 28, 2024.
• The SPA also included a concurrent private placement of warrants, exercisable immediately until the earlier of three and a half years from issuance or 30 days after the FDA accepts an NDA for cytisinicline.
• Bencich also owns 10,000 common stock warrants with an exercise price of $4.906.
• An administrative error from a 1-for-20 stock split on July 31, 2020, was corrected, decreasing Bencich's previously reported ownership by 6 shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the CEO's investment in the company, which suggests confidence. However, it's also related to a capital raise, which can sometimes be viewed with mixed feelings.

Positives

• The CEO's purchase of shares may signal confidence in the company's future prospects.

Future Outlook

The warrants are exercisable until the earlier of three and one-half years after issuance or 30 days following the Issuer's public disclosure of the acceptance of an NDA for cytisinicline by the FDA.

Industry Context

Insider buying is often viewed positively by investors, as it can indicate management's confidence in the company's prospects. This purchase is related to a financing event, which is common in the biotech industry to fund drug development.

Stakeholder Impact

• The CEO's purchase could positively influence shareholder sentiment.
• The capital raise will provide the company with additional funds, potentially benefiting employees and other stakeholders through continued operations and development.

Key Dates